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Summary
Objectives: Statins are widely administered to patients with acutemyocardial infarc-
tion (AMI), but knowledge of the effects of early statin therapy on the long-term
mortality of AMI patients after stent implantation is still limited, especially for
beyond low-density lipoprotein cholesterol (LDL-C) lowering effects.
Methods: Our 378 consecutive AMI patients who were discharged alive from the hos-
pital with successful stent implantation between 1997 and 2005 were included. We
retrospectively evaluated the effects of statin therapy on major adverse cardiovas-
cular events (MACE), including all-cause death, reinfarction, coronary artery bypass
grafting, heart failure requiring rehospitalization, and target lesion revasculariza-
tion.
Results: Statins were given to 271 patients according to the physician to achieve a
LDL-C level of less than 100mg/dL. The achieved LDL-C levels in the statin group
were 100.7, 95.1, 96.7, and 102.8mg/dL at discharge, 6 months, 1 year, and 3
years, respectively, whereas those in the non-statin group were 103.2, 107.3, 102.8,e levels were not signiﬁcantly different between the groupsand 103.0mg/dL. Thes
during 3 years. Based on Kaplan—Meier estimates, statin therapy was associated
with a reduction of long-term mortality (log-rank test P = 0.007). Multivariate Cox
regression analysis revealed that statin therapy (P = 0.015, hazard ratio: 0.10; 95%
conﬁdence interval: 0.01—0.64) was a signiﬁcant predictor of favorable prognosis.
Multivariate analysis revealed that statin treatment had a beneﬁcial effect against
MACE over 3 years (P = 0.008).
∗ Corresponding author. Tel.: +81 72 445 1000; fax: +81 72 441 8812.
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914-5087/$ — see front matter © 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.jjcc.2008.02.003
172 S. Kadota et al.
Conclusions: Early statin therapy was beneﬁcial for long-term mortality of AMI
patients treated with stenting.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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line LDL-C was <100mg/dL, further LDL-lowering
therapy was not required at the observed period
[13]. Statins were not prescribed for those with a© 2008 Japanese Colleg
reserved.
3-hydroxy-3-methylglutaryl coenzyme A reduc-
tase inhibitors (statins) have been proven to reduce
long-term cardiac events and mortality in patients
with stable coronary artery disease (CAD) [1—3].
Furthermore, early initiation of statins after acute
coronary syndrome (ACS) was revealed to be ben-
eﬁcial in randomized controlled trials (RCT) [4—6]
and observational studies [7,8]. Stent implantation
is the ﬁrst-line therapy for acute myocardial infarc-
tion (AMI); however, in a large-scale RCT such as
the Z phase of the A to Z trial, less than half
of all patients were treated with percutaneous
coronary intervention (PCI) [5]. Statin therapy for
stable or unstable CAD following PCI (with stent-
ing 55—56%) has been shown to reduce recurrent
cardiac events over 3 to 4 years [9]. Recently, the
MUSASHI-AMI trial showed that early statin ther-
apy for Japanese with AMI after PCI (with stenting
81—82%) reduced recurrent cardiovascular events,
in particular congestive heart failure, for up to 2
years [6].
Although all these trials concluded that the
effects of statins are related to the reduction
of low-density lipoprotein cholesterol (LDL-C),
statins may possess so-called pleiotropic effects,
including plaque stabilization, anti-inﬂammation,
anti-thrombogenicity, enhanced arterial compli-
ance, blood pressure reduction, and modulation
of vascular and ventricular functions [10—12].
To clarify the beyond LDL-C lowering effects
of statins, it is worthwhile to compare cardio-
vascular events in patients whose LDL-C levels
achieved guideline-based level between groups
with and without statins. Therefore we inves-
tigated the long-term effects of statin therapy
for AMI patients treated with stent implantation,
whose LDL-C levels were stabilized at approxi-
mately 100mg/dL.
Methods
Study populationWe retrospectively analyzed the data of 378
consecutive patients with AMI who were dis-
charged alive from Kishiwada City Hospital with
successful stent implantation between January
l
n
t
f997 and December 2005. To conﬁrm AMI sta-
us, ischemic symptoms or electrocardiographic
hanges accompanied by a cardiac troponin T
evel >0.10 ng/ml were required. On admission,
nformation such as patient’s age, gender, risk
actors (diabetes mellitus, hypertension, hyperlipi-
emia, smoking history), previous MI or coronary
rtery bypass grafting (CABG) and lipid proﬁle
total cholesterol [TC], high-density lipoprotein
holesterol [HDL-C], triglyceride, and LDL-C)
as collected. Hyperlipidemia was deﬁned as
C≥ 220mg/dL, HDL-C < 40mg/dL, TG≥ 150mg/dL
nd/or having received medication. Diabetes mel-
itus was deﬁned according to World Health
rganization criteria, and/or having received med-
cation. Hypertension was deﬁned as systolic blood
ressure ≥140mmHg, diastolic blood pressure
90mmHg and/or on medication. During hospital-
zation, other variables were recorded regarding
iochemical markers, echocardiography, quanti-
ative gated single photon emission computed
omography, intervention procedure and major
omplications. Creatine kinase (CK) was measured
mmediately after the procedure, every 4 h until
he peak.
reatment
tents were placed according to standard proto-
ols. Patients were pretreated before intervention
ith aspirin 100mg and cilostazol 50mg. They
eceived intravenous heparin during the procedure
ith a target activated clotting time of >300 s. After
tenting, all patients received aspirin 100mg once
r twice daily for as long as possible and ticlo-
idine 100mg twice daily for at least 1 month.
tatins were given within 24 h of hospital admission,
ccording to the physician, to achieve an LDL-C
evel <100mg/dL before discharge. More intensive
egimen may be appropriate today, however, the
oal <100mg/dL was optimal and, if the base-ow LDL-C level on admission (mean 102.7mg/dL;
on-statin group); however, statins were added for
he non-statin group during follow-up, if necessary,
rom an ethical point of view. Treating physicians
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seyond LDL-C lowering effects of statins
ere also allowed to change the dosage of statins
nd to switch the original statin to another statin
uring follow-up. Concomitant therapy with beta-
drenergic blocking agents, angiotensin-converting
nzyme (ACE) inhibitors or angiotensin II receptor
lockers (ARB), calcium channel blockers, diuret-
cs or nitrates was left to the discretion of the
hysician.
After discharge, follow-up angiography was per-
ormed at around 6 months and the lipid proﬁle
as measured at 6 months, 1 year and 3 years.
e analyzed major adverse cardiovascular events
MACE), including all-cause death, reinfarction,
ABG, heart failure required rehospitalization, and
arget lesion revascularization (TLR) at 6 months, 1
ear and 3 years.
tatistical analysis
ll descriptive data are expressed as the
ean± standard deviation (S.D.). StatFlex V5.0
tatistical software for Windows (Artek Inc., Osaka,
apan) was used for all statistical analyses. All
nalyses were performed on an intention-to-
reat basis. Comparisons of continuous variables
etween groups were analyzed by t test (2-sided)
nd comparisons of categorical variables were
enerated with the chi-square test. Probabil-
ty values <0.05 were considered statistically
igniﬁcant.
Long-term mortality was estimated using
aplan—Meier techniques, and the impact of
tatin therapy as a time-dependent covariate
n patient outcome was evaluated with the Cox
roportional hazards regression model. Univariate
ox regression analysis was performed to evaluate
he inﬂuence of variables; age, gender, LVEF, ST
levation, peak CK, anterior myocardial infarction,
umber of narrowed coronary arteries, LMT≥ 50%
tenosis, C-reactive protein, TC, HDL-C, triglyc-
ride and LDL-C levels on admission, decrease
f LDL-C during hospitalization, statins, ACE
nhibitors/ARB, beta blockers, calcium channel
lockers, diuretics, nitrates, diabetes mellitus,
ypertension, hyperlipidemia, smoking history,
umber of stents, stent diameter, total length
f stents, and PCI for non-IRA. Variables with a
≤ 0.20 on univariate analyses were included in
he multivariate model. Univariate analysis of
atients with and without MACE over 3 years were
erformed using the same variables used with
nivariate Cox regression analysis. Multivariate
ogistic regression analysis was used to adjust for
ll variables with a P < 0.20 on univariate analysis
ssociated with MACE over 3 years.
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esults
atients
aseline characteristics and clinical events dur-
ng follow-up (mean± S.D., 1129± 857 days) were
ollected. Overall, 271 (72%) patients including 3
amilial hypercholesterolemias were given statins
ithin 24 h after admission. Among them, 4 patients
ad been taking statin before AMI. Pravastatin,
torvastatin, simvastatin and ﬂuvastatin were given
o 139 (53%), 89 (33%), 42 (15%) and 1 patients,
espectively. Mean doses were 10.5, 11.3, 5.3 and
0mg, respectively. During follow-up, 36 patients
n the non-statin group had an increased LDL-C
evels necessitating initiation of statin therapy. Of
hem, 22 and 27 patients initiated statin therapy,
ithin the ﬁrst 6 months and 1 year, respectively.
ther lipid lowering drugs were added on for 3
atients in the non-statin group. The baseline char-
cteristics of the two groups are shown in Table 1.
n the statin group, there were more female and
ounger patients. More ACE inhibitors or ARB and
eta-blockers, and fewer nitrates were prescribed
or the statin group. Both groups had similar culprit
esions but the statin group had more PCI in non
nfarct-related artery (IRA) during hospitalization.
ipid proﬁle
t the time of admission, serum lipid levels were
igniﬁcantly different between the two groups
Table 1). The mean LDL-C levels in statin group
trikingly decreased to 100.7mg/dL during hospi-
alization and achieved the goal, <100mg/dL, after
months and 1 year, but increased slightly after
years. In contrast, those in the non-statin group
ere all between 100 and 110mg/dL, as shown
n Fig. 1. The difference of LDL-C levels between
he two groups during the 3 years after admission
as not signiﬁcant with two-factor mixed design
ith repeated measures in one-factor analysis. The
chieved HDL-C levels in statin group were 41.7,
2.1, 51.1, and 51.0mg/dL at discharge, 6 months,
year, and 3 years, respectively, whereas those
n the non-statin group were 42.4, 49.9, 48.9,
nd 48.5mg/dL. The difference of HDL-C levels
etween the two groups during 3 years was not
igniﬁcant.ong-term mortality and MACE
aplan—Meier curves in the two groups are shown
n Fig. 2, and the log-rank test revealed that
tatin therapy was associated with the reduction
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Table 1 Baseline characteristics of patients
Statin group Non-statin group P-value
N 271 107
Male, no. (%) 184 (68) 86 (81) 0.016
Age (y) 65.6± 11.6 69.0± 11.5 0.009
LVEF (%) 57.3± 14.0 59.1± 14.7 0.30
<40%, no. (%) 26 (10) 10 (9) 0.84
ST elevated MI, no. (%) 204 (75) 79 (74) 0.77
Peak creatine kinase (IU/L) 2532.9± 2359.4 2107.1± 2159.0 0.11
Prior MI, no. (%) 19 (7) 9 (8) 0.64
Prior CABG, no. (%) 1 (0) 2 (2) 0.14
Culprit location, no. (%) 0.79
Anterior 129 (48) 52 (49)
Inferior 110 (41) 45 (42)
Lateral 32 (12) 10 (9)
No. of narrowed coronary arteries 2.0± 0.8 1.9± 0.8 0.24
Single, no. (%) 82 (30) 37 (35)
Double, no. (%) 101 (37) 44 (41)
Triple, no. (%) 88 (32) 26 (24)
LMT ≥50% stenosis, no. (%) 26 (10) 8 (7) 0.52
Lipid proﬁle on admission
Total cholesterol (mg/dL) 212.2± 39.7 168.6± 34.2 <0.0001
HDL-C (mg/dL) 49.3± 14.1 45.4± 12.2 0.023
Triglyceride (mg/dL) 145.4± 134.8 106.1± 63.6 0.004
LDL-C (mg/dL) 133.5± 38.3 102.7± 31.9 <0.0001
C-reactive protein (mg/dL)
On admission 0.46± 1.86 1.49± 4.11 0.006
After 6 months 0.10± 0.54 0.25± 0.97 0.11
Risk factor, no. (%)
Diabetes mellitus 90 (33) 26 (24) 0.091
Hypertension 136 (50) 49 (46) 0.44
Hyperlipidemia 224 (83) 35 (32) <0.0001
Smoking history 129 (48) 56 (52) 0.36
Concomitant drugs, no. (%)
ACE inhibitors/ARB 223 (82) 76 (71) 0.015
Beta-blockers 181 (67) 54 (50) 0.003
Calcium channel blockers 37 (14) 18 (17) 0.43
Diuretics 42 (15) 20 (19) 0.45
Nitrates 119 (44) 65 (61) 0.003
Stent proﬁle
Diameter (mm) 3.11± 0.46 3.14± 0.41 0.55
<3.0mm, no. (%) 50 (18) 15 (14) 0.30
No. of stents 1.2± 0.5 1.2± 0.6 0.92
One, no. (%) 217 (80) 89 (83)
Two, no. (%) 46 (17) 13 (12)
More than two, no. (%) 8 (3) 5 (5)
Total length (mm) 20.4± 8.3 18.7± 8.1 0.11
Type, no. (%) 0.014
Multilink 95 (35) 49 (46)
S660,670 68 (25) 27 (25)
Driver 65 (24) 8 (7)
Nir 13 (5) 10 (9)
Cypher 8 (3) 2 (2)
Others* 22 11
PCI for non-IRA, no. (%) 77 (28) 13 (12) 0.001
ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers; CABG, coronary artery bypass grafting; HDL-C, high-
density lipoprotein cholesterol; IRA, infarct-related artery; LDL-C, low-density lipoprotein cholesterol; LMT, left main trunk; LVEF,
left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.
* Others included Palmaz, Tsunami, GFX, TERUMO, and, Express.
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sigure 1 The difference of low-density lipoprotein cho
uring the 3 years was not signiﬁcant using a two-factor m
f long-term mortality signiﬁcantly (P = 0.007). Dur-
ng follow-up, 16 patients died, including 4 cardiac
eaths. Age (P = 0.025), LVEF (P = 0.009), peak CK
P = 0.020) and statin use (P = 0.012, hazard ratio
HR]: 0.27, 95% conﬁdence interval [CI]: 0.09—0.75)
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Table 2 Predictors of long-term mortality in univariate Co
Variable
Male
Age (y)
LVEF (%)
ST elevation
Peak creatine kinase (IU/L)
Anterior myocardial infarction
No. of narrowed coronary arteries
LMT >50% stenosis
C-reactive protein on admission (mg/dL)
Total cholesterol on admission (mg/dL)
HDL-C on admission (mg/dL)
Triglyceride on admission (mg/dL)
LDL-C on admission (mg/dL)
Decrease of LDL-C during hospitalization (mg/dL)
Diabetes mellitus
Hypertension
Hyperlipidemia
Smoking history
Statins
ACE inhibitors/ARB
Beta blockers
Calcium channel blockers
Diuretics
Nitrates
Stent diameter (mm)
No. of stents
Total length of stents (mm)
PCI for non-IRA
ACE, angiotensin converting enzyme; ARB, angiotensin II receptor b
tein cholesterol; IRA, infarct-related artery; LDL-C, low-density lipo
ejection fraction; PCI, percutaneous coronary intervention.rol (LDL-C) levels between statin and non-statin groups
d design with repeated measures on one-factor analysis.
igniﬁcantly inﬂuence prognosis with univariate
ox regression analysis (Table 2). A multivariate
ox proportional hazards regression model includ-
ng age, LVEF, peak CK, TC and LDL-C levels on
dmission, hypertension, hyperlipidemia, statin,
x regression analysis
Hazard ratio 95%CI P-value
2.54 0.57—11.2 0.22
1.74 (+10) 1.07—2.81 0.025
1.69 (−10) 1.14—2.51 0.009
2.53 0.57—11.1 0.22
1.19 (+1000) 1.03—1.37 0.020
1.83 0.66—5.05 0.24
1.16 0.60—2.25 0.65
1.55 0.35—6.83 0.56
0.99 (+1.0) 0.82—1.19 0.93
0.90 (+10) 0.80—1.01 0.061
0.86 (+10) 0.52—1.42 0.55
0.98 (+10) 0.92—1.05 0.53
0.90 (+10) 0.77—1.04 0.16
0.95 (+10) 0.81—1.10 0.46
1.47 0.53—4.06 0.46
2.33 0.81—6.72 0.12
0.47 0.17—1.24 0.12
1.33 0.47—3.76 0.59
0.27 0.09—0.75 0.012
0.86 0.28—2.66 0.79
0.80 0.30—2.16 0.66
1.37 0.39—4.84 0.62
2.74 0.95—7.90 0.063
0.60 0.19—1.72 0.32
1.32 (−0.5) 0.86—2.00 0.20
1.10 0.50—2.45 0.81
1.12 (+5) 0.83—1.50 0.45
0.24 0.03—1.85 0.17
lockers; CI, conﬁdence interval; HDL-C, high-density lipopro-
protein cholesterol; LMT, left main trunk; LVEF, left ventricular
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Figure 2 Cumulative survival curves revealed that statin
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showed that statin therapy was the signiﬁcanttherapy was associated with the reduction of the long-
term mortality signiﬁcantly (P = 0.007).
diuretics, stent diameter, and PCI for non-IRA
revealed that statin therapy (P = 0.015, HR: 0.010,
95%CI: 0.01—0.64), age (P = 0.022, HR: 2.55 for a
10 year increment, 95%CI: 1.14—5.65) and peak
CK (P = 0.032, HR: 1.30 for a 1000 IU/L increment,
95%CI: 1.02—1.66) were signiﬁcant predictors of
prognosis (Table 3).
The incidences of MACE in both groups were not
signiﬁcantly different at 6 months, and at 1 year,
however, they were almost different at 3 years
(P = 0.053). Between patients treated with pravas-
tatin and those with atorvastatin, there were no
signiﬁcant differences in MACE. Univariate analy-
ses showed that patients with MACE over 3 years
p
r
o
l
Table 3 Multivariate Cox proportional hazards regression m
Variable Hazard
Statins 0.10
Age (y) 2.55 (+
Peak creatine kinase (IU/L) 1.30 (+
Hyperlipidemia 3.82
Stent diameter (mm) 1.58 (−
Total cholesterol on admission (mg/dL) 1.19 (+
LVEF (%) 1.26 (−
LDL-C on admission (mg/dL) 0.87 (+
Diuretics 0.45
Hypertension 1.65
PCI for non-IRA 0.61
CI, conﬁdence interval; IRA, infarct-related artery; LDL-C, low-den
ventricular ejection fraction; PCI, percutaneous coronary interventS. Kadota et al.
ended to have low LVEF, more diabetes, had
eceived fewer statins, more diuretics and smaller
tents. Multiple logistic regression analysis includ-
ng LVEF, diabetes mellitus, anterior MI, statin,
CE inhibitors/ARB, diuretics, and stent diameter
howed that statin usage (P = 0.008, odds ratio:
.36, 95%CI: 0.19—0.84) and LVEF (P = 0.037, odds
atio: 1.40 for a 10% reduction, 95%CI: 1.01—1.91)
ere independent predictors of MACE over 3 years
Table 4). Those who were added statins during
ollow-up in non-statin group did not have a higher
vent rate (15/36) than the others (25/71).
afety and tolerability
ine patients discontinued statin treatment due to
iver dysfunction (5/271), skin rash (1/271), change
o ﬁbrates (1/271), and excess lowering of the LDL-
level (2/271). No patient developed myopathy.
iscussion
mong AMI patients treated with stent implantation
nd whose LDL-C levels were stabilized at around
00mg/dL, the early initiation of statin treatment
as associated with the signiﬁcant reduction of
ong-term mortality and the rate of MACE over 3
ears, when compared with non-statin treatment.
lthough, low-dose statins were administered, the
ong-term effects were beneﬁcial. Despite the
triking decrease of LDL-C levels following treat-
ent, the multivariate Cox regression analysisredictor of long-term mortality above the LDL-C
eduction or lipid proﬁles; therefore the beneﬁt
f statin therapy may be related to beyond LDL-C
owering effects.
odel of long-term mortality
ratio 95%CI P-value
0.01—0.64 0.015
10) 1.14—5.65 0.022
1000) 1.02—1.66 0.032
0.62—23.52 0.15
0.5) 0.84—2.96 0.15
10) 0.84—1.69 0.32
10) 0.72—2.19 0.42
10) 0.61—1.23 0.42
0.05—3.90 0.47
0.38—6.99 0.50
0.06—5.56 0.66
sity lipoprotein cholesterol; LMT, left main trunk; LVEF, left
ion.
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Table 4 Multiple logistic regression analysis of major adverse cardiovascular events in 3 years
Variable Odds ratio 95%CI P-value
Statins 0.36 0.16—0.77 0.008
LVEF (%) 1.40 (−10) 1.01—1.91 0.038
Diabetes mellitus 2.13 0.97—4.66 0.059
ACE inhibitors/ARB 2.71 0.92—7.99 0.071
Stent diameter (mm) 1.35 (−0.5) 0.91—2.00 0.14
Diuretics 1.59 0.50—5.05 0.43
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wAnterior myocardial infarction 0.97
ACE, angiotensin converting enzyme; ARB, angiotensin II recep
fraction.
In the MIRACL [4] and PROVE IT-TIMI 22 trials
14], beneﬁcial effects of statins were observed
n a short period, such as 4 months. In contrast,
n patients with stable CAD, Kaplan—Meier curves
how little detectable difference in the ﬁrst [1,3]
r second years [2]. Our results showed that the
eneﬁts of statins were not statistically signiﬁ-
ant during the ﬁrst 6 months and 1 year. Two
ecent meta-analyses also suggested that the ben-
ﬁt of early statin initiation for ACS took more
han 4 months to become apparent [10,15]. The
ime-course difference of statin effects between
he MIRACL and PROVE IT-TIMI 22 trials and our
tudy may be explained by the speciﬁc atorvastatin
se of these trials, however, the majority of our
tudy used pravastatin and there were no signiﬁcant
ifferences in MACE between pravastatin and ator-
astatin. The difference of stent implantation may
lso explain the early inconsistent response; in our
tudy, all patients received stents but in the other
rials, the rate of PCI was 0% and 69%, respectively.
The MUSASHI-AMI trial revealed that the early
nitiation of statin treatment reduced recurrent
ardiovascular events, in particular, congestive
eart failure for Japanese AMI patients treated
ith PCI [6]. Both the MUSASHI-AMI trial and our
tudy included AMI patients treated with stent
mplantation, which may reﬂect the most common
ituation encountered in clinical practice. How-
ver, previous studies including MUSASHI-AMI could
ot differentiate statin’s beneﬁcial effects of LDL-
lowering or beyond LDL-C lowering, because
he achieved LDL-C levels were signiﬁcantly dif-
erent between groups with and without statins.
n the present study, the achieved LDL-C levels
ere not signiﬁcantly different; thus, statin ther-
py would show beyond LDL-C lowering effects.
DL-C levels also could not explain the difference in
ortality.
Meta-analysis of early statin initiation for ACS
id not show any signiﬁcant relation between the
eduction in LDL-C level and event-risk reduction
10]. These results also revealed that statins should
[
t
l
t0.43—2.14 0.93
lockers; CI, conﬁdence interval; LVEF, left ventricular ejection
ave beyond LDL-C lowering effects; pleiotropic
ffects. Data from PROVE IT-TIMI 22 demonstrate
learly that the decrease in C-reactive protein can
e modulated by the dose of statin therapy [14]. In
ur data, there was no signiﬁcant difference of the
-reactive protein level over 6 months between the
tatin group and non-statin group. The mechanism
y which statin therapy improves survival in AMI
atient after stenting is unclear, but some unmea-
urable factors, in addition to plaque stabilization
nd prevention of atheroma development, may be
esponsible for the present ﬁndings.
Although, the lack of placebo-controlled, ran-
omized design could be regarded as a limitation
f the present study, a placebo-controlled design
ay be difﬁcult to justify on ethical grounds given
he well-established effects of statins on secondary
revention. During follow-up, about 34% of patients
n the non-statin group were necessitated to treat
ith statins because the LDL-C levels were ele-
ated. This is also a limitation on ethical point of
iew, however, the effects of statins may be dif-
erent for the patients who treated after the acute
hase immediately. Moreover, because statin treat-
ent was initiated only for patients with elevated
DL-C levels, the data do not allow us to deter-
ine how aggressively the LDL-C level should be
owered. The guideline was updated, as an option,
o an LDL-C goal <70mg/dL when the risk is very
igh, as in ACS [16], however, it was appropri-
te at the beginning period, 1997, to refer to an
DL-C level of 100mg/dL as ‘‘low’’. Ethnic differ-
nces could have also made different responses to
tatin therapy. The subanalysis of MUSASHI-AMI trial
ecently reported that pravastatin was superior to
ipophilic statin including atorvastatin at presenting
ew Q-wave appearance and reducing cardiovascu-
ar events, even though the achieved LDL-C level
as signiﬁcantly higher (107mg/dL vs 90mg/dL)
17]. There was no signiﬁcant association between
he reduction of mortality or MACE and an LDL-C
evel <70mg/dL in our study (data were not shown);
herefore, further research is required to deter-
[[
[
[
[
[
[178
mine whether the updated goal could apply just as
much to Japanese.
In conclusion, our results suggest that early
statin initiation for AMI with stent implantation was
associated with a great beneﬁt for long-term mor-
tality. Further clinical studies are needed to conﬁrm
beyond LDL-C lowering effects of statins.
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